Asia Tech Wire (Aug 15) -- Eli Lilly has sent a wave of cease-and-desist letters to U.S. healthcare providers in recent days, asking the industry to stop promoting copycat weight-loss drugs.

The notification letters bear the signatures of numerous attorneys at Kirkland & Ellis LLP.

Despite the increased availability of Mounjaro and Zepbound, Eli Lilly's weight loss drugs, the U.S. diet pill market continues to suffer from an oversupply problem.

It's worth noting that the U.S. Food and Drug Administration (FDA) has tacitly allowed dispensers to offer copycat drugs as long as there are drug supply shortages.